

Published in final edited form as:

Eur J Neurol. 2014 ; 21(1): e2.

Pure hereditary spastic paraplegia due to a de-novo mutation in the *NIPA1* gene

David Arkadir, MD PhD¹, Anne Noreau, MsC^{2,3}, Jill S. Goldman, MS MPhil¹, Guy A. Rouleau, MD PhD³, and Roy N. Alcalay, MD MS¹

¹The Departments of Neurology, Columbia University Medical Center, NYC, NY, USA

²Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada, H2L 4M1

³Montréal Neurological Institute and Hospital, McGill, Montreal, Quebec, Canada, H3A 2B4

Keywords

Spasticity; hereditary; spastic paraplegia; mutation; gene

Hereditary spastic paraplegia (HSP) is a group of diseases with heterogeneous mode of inheritance and is characterized primarily by progressive spasticity of the lower limbs due to degeneration of long pyramidal tract. HSP type 6 (SPG6) is caused by mutations in the *NIPA1* gene [1] (OMIM #600363) and accounts for less than 1% of autosomal dominant cases among Caucasians patients [2]. Traditionally, SPG6 was considered a pure (uncomplicated) form of HSP. Recent observations, however, expanded the phenotypic spectrum and linked *NIPA1* mutations to some cases of more complex forms of HSP [3, 4]. We report here a family with a pure form of HSP due to a *de novo* transition mutation in the *NIPA1* gene.

The three affected members of the family were a 46 year-old parent and two children, aged 21 and 15 years of age. They all developed slowly progressive spastic gait that started during the first half of their second decade of life. Medical history was absent except for mild delayed speech development and attention deficit in the younger child and a single questionable generalized seizure in the older child that was not documented on electroencephalogram. This episode included a sudden loss of consciousness, lasted only few seconds and was associated with tongue biting and twitching of the left fingers but

*Corresponding author: David Arkadir, Columbia Medical Center, 710 West 168th St, NYC, NY 10023; Tel: 212.305.3767, Fax: 212.305.1304, arkadir@gmail.com.

Disclosures:

- David Arkadir reports no disclosures
- Anne Noreau reports no disclosures
- Jill S. Goldman reports no disclosures
- Guy A. Rouleau reports no disclosures
- Roy N. Alcalay reports no disclosures

without clear postictal period. The proband, 36 years after symptom onset, had difficulty ambulating and was assisted by a walker. Both children had spastic gait but walked without assistance. Neurological examination of the affected family members was significant for marked spasticity, mild weakness of hip extensors, bilateral ankle clonus, globally hyperactive deep tendon reflexes that were more prominent in the lower extremities and extensor plantar responses. Cognition, ocular movements and cerebellar functions were all normal.

Sequencing of the *NIPA1* gene (Athena Diagnostics, Inc) revealed in all the affected family members a point mutation causing transition from adenine to guanine (G→A) at position 316. This mutation led to an amino acid change, from glycine to arginine, in codon 106. This specific mutation has been previously reported as pathogenic [3, 5] of a pure form of HSP, although cases of complicated HSP with epilepsy have been also documented [3]. Other ancillary tests included brain MRI studies, genetic testing for other autosomal dominant HSPs (SPG3A, SPG4 and SPG31) and extensive metabolic work-up were all normal. An MRI study of the proband's thoracic spine showed spinal cord atrophy.

Lack of symptoms or clinical signs in the parents of the proband led us to test them for a mutation in the *NIPA1* gene (after they signed an informed consent for a research protocol approved by Columbia University IRB). The mutation was not present in the non-manifesting parents of the proband. True parenthood was confirmed using a panel of six highly informative unlinked microsatellite markers. To ensure specificity of this method, genetic polymorphism was also tested by three CEPH (1331-1, 1332-12, 1347-1) and showed perfect concordance.

This finding supports the hypothesis that this was a *de novo* mutation. According to our knowledge, *de novo* mutations were never documented to cause SPG6 although such mutations were sparsely documented in other HSPs [6]. This finding strengthens the assumption that this is a pathogenic mutation and emphasizes the need to consider autosomal dominant HSP even in the absence of family history.

Acknowledgments

Funding:

- David Arkadir fellowship is supported by the Parkinson's Disease Foundation (PDF).
- Anne Noreau holds a Doctoral Award - Frederick Banting and Charles Best Graduate Scholarship by the Canadian Institutes of Health Research (CIHR).
- Guy A. Rouleau holds the Canada Research Chair for the Genetics of Brain Diseases and is supported by the RMGA and the Canadian Institutes of Health Research.
- Roy N. Alcalay receives research support from the NIH (K02NS080915), the Parkinson's Disease Foundation, the Smart Foundation and the Michael J Fox foundation.

References

1. Rainier S, Chai JH, Tokarz D, Nicholls RD, Fink JK. *NIPA1* gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). *American journal of human genetics*. 2003; 73(4): 967–971. Epub 2003/09/26. [PubMed: 14508710]

2. Klebe S, Lacour A, Durr A, Stojkovic T, Depienne C, Forlani S, et al. NIPA1 (SPG6) mutations are a rare cause of autosomal dominant spastic paraplegia in Europe. *Neurogenetics*. 2007; 8(2):155–157. Epub 2007/01/06. [PubMed: 17205300]
3. Svenstrup K, Moller RS, Christensen J, Budtz-Jorgensen E, Gilling M, Nielsen JE. NIPA1 mutation in complex hereditary spastic paraplegia with epilepsy. *European journal of neurology : the official journal of the European Federation of Neurological Societies*. 2011; 18(9):1197–1199. Epub 2011/05/24. [PubMed: 21599812]
4. Du J, Hu YC, Tang BS, Chen C, Luo YY, Zhan ZX, et al. Expansion of the phenotypic spectrum of SPG6 caused by mutation in NIPA1. *Clinical neurology and neurosurgery*. 2011; 113(6):480–482. Epub 2011/03/23. [PubMed: 21419568]
5. Beetz C, Schule R, Klebe S, Klimpe S, Klopstock T, Lacour A, et al. Screening of hereditary spastic paraplegia patients for alterations at NIPA1 mutational hotspots. *Journal of the neurological sciences*. 2008; 268(1–2):131–135. Epub 2008/01/15. [PubMed: 18191948]
6. Rainier S, Sher C, Reish O, Thomas D, Fink JK. De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy. *Archives of neurology*. 2006; 63(3):445–447. Epub 2006/03/15. [PubMed: 16533974]